Treatment of cognitive deficits in schizophrenia

Current Opinion in Investigational Drugs

Volumn 7, Issue 7, 2006, Pages 608-613

  Bowie, Christopher R ^a   Harvey, Philip D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Cognitive deficits; Pharmacological augmentation; Schizophrenia

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOZAPINE; DONEPEZIL; DOPAMINE 1 RECEPTOR STIMULATING AGENT; GALANTAMINE; GLYCINE RECEPTOR AGONIST; GUANFACINE; HALOPERIDOL; MIANSERIN; MODAFINIL; NEUROLEPTIC AGENT; NICOTINIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; RIVASTIGMINE; TANDOSPIRONE; ZIPRASIDONE;

ADD ON THERAPY; ADJUVANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; LOW DRUG DOSE; MEMORY DISORDER; META ANALYSIS; NAUSEA; NONHUMAN; PSYCHOSOCIAL CARE; REMISSION; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; BRAIN; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33745791791     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: A meta-analysis of the outcome literature. Am J Psychiatry (1994) 151(10):1409-1416.
2. Milev P, Ho BC, Arndt S, Andreasen NC: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. Am J Psychiatry (2005) 162(3):495-506.
3. Harvey PD, Parrella M, White L, Mohs RC, Davidson M, Davis KL: Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res (1999) 35(1):77-84.
4. Marder SR, Fenton W: Measurement and treatment research to improve cognition in schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res (2004) 72(1):5-9.
5. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woemer MG, Geisler S et al: Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. Am J Psychiatry (2000) 157(4):549-559.
6. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC: Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry (1994) 51(2):124-131.
7. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M: Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry (1999) 156(9):1328-1335.
8. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV: Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry (2001) 58(1):24-32.
9. Addington J, Addington D, Gasbarre L: Distractibility and symptoms in schizophrenia. J Psychiatry Neurosci (1997) 22(3):180-184.
10. Harvey PD, Silverman JM, Mohs RC, Parrella M, White L, Powchik P, Davidson M, Davis KL: Cognitive decline in late-life schizophrenia: A longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry (1999) 45(1):32-40.
11. Friedman JI, Harvey PD, Coleman T, Moriarty PJ, Bowie C, Parrella M, White L, Adler D, Davis KL: Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: A comparison with Alzheimer's disease and normal aging. Am J Psychiatry (2001) 158(9):1441-1448.
12. Harvey PD, Parrella M, White L, Mohs RC, Davidson M, Davis KL: Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res (1999) 35(1):77-84.
13. Harvey PD, Siu CO, Romano S: Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (2004) 172(3):324-332.
14. Addington J, Addington D: Neurocognitive functioning in schizophrenia: A trial of risperidone versus haloperidol. Can J Psychiatry (1997) 42(9):983.
15. Mishara AL, Goldberg TE: A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biol Psychiatry (2004) 55(10):1013-1022.
16. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J: The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone. Biol Psychiatry (2002) 51(12):972-978.
17. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM et al: Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry (2006) 59(2):97-105.
18. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M: Treatment of cognitive impairment in early psychosis: A comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry (2005) 162(10):1888-1895.
19. Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RS, Katz S, Frecska E: Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry (1995) 152(2):197-207.
20. Strauss ME, Reynolds KS, Jayaram G, Tune LE: Effects of anticholinergic medication on memory in schizophrenia. Schizophr Res (1990) 3(2):127-129.
21. Harvey PD, Keefe RS: Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry (2001) 158(2):176-184.
22. Keefe RS, Seidman U, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD et al: Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry (2004) 161(6):985-995.
23. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ: Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res (2004) 66(2-3):101-113.
24. Harvey PD, Siu CO, Romano S: Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (2004) 172(3):324-332.
25. Harvey PD, Napolitano J, Mao L, Gharabawi G: Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry (2003) 18(9):820-829.
26. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M et al: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 159(6):1018-1028.
27. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ: Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res (2004) 66(2-3):101-113.
28. Harvey PD, Bowie CR, Loebel A: Neuropsychological normalization with long-term atypical antipsychotic treatment, Results of a six-month randomized, double-blind comparison of ziprasidone vs olanzapine. J Neuropsychiatry Clin Neurosci (2006) 18(1):54-63.
29. Davidson M, Harvey PD, Bergman RL, Powchik P, Kaminsky R, Losonczy MF, Davis KL: Effects of the D-1 agonist SKF-38393 combined with haloperidol in schizophrenic patients. Arch Gen Psychiatry (1990) 47(2):190-191.
30. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL: Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology (2001) 25(3):402-409.
31. Buchanan RW, Summerfelt A, Tek C, Gold J: An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res (2003) 59(1):29-33.
32. MacEwan GW, Ehmann TS, Khanbhai I, Wrixon C: Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatr Scand (2001) 104(6):469-472.
33. Risch SC, McGurk S, Horner MD, Nahas Z, Owens SD, Molloy M, Gilliard C, Christie S, Markowitz JS, DeVane CL, Mintzer J et al: A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates. Neurocase (2001) 7(2):105-110.
34. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA: Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol (2005) 28(4):179-184.
35. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL: A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry (2002) 51(5):349-357.
36. Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A: A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol (2004) 7(2):117-123.
37. Freudenreich O, Herz L, Deckersbach T, Evins AE, Henderson DC, Cather C, Goff DC: Added donepezil for stable schizophrenia: A double-blind, placebo-controlled trial. Psychopharmacology (2005) 181(2):358-363.
38. Stryjer R, Strous RD, Bar F, Werber E, Shaked G, Buhiri Y, Kotler M, Weizman A, Rabey JM: Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol (2003) 26(1):12-17.
39. Bora E, Veznedaroglu B, Kayahan B: The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol (2005) 28(3):139-141.
40. Sharma TS, Kumari M: Cognitive effects of adjunctive 24-week rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation. Schizophr Res (2006): in press.
41. Kumari V, Aasen I, Ffytche D, Williams SC, Sharma T: Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study. Neuroimage (2006) 29(2):545-556.
42. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M: D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry (2005) 57(6):577-585.
43. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC: High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry (2004) 55(2):165-171.
44. Harvey PD, Serper MR, White L, Parrella MJ, McGurk SR, Moriarty PJ, Bowie C, Vadhan N, Friedman J, Davis KL: The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr Psychiatry (2001) 42(4):306-313.
45. Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC: The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr Res (2004) 68(1):11-19.
46. Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT: A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry (1999) 56(1):21-27.
47. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D: A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (2005) 179(1):144-150.
48. Barch DM, Carter CS: Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res (2005) 77(1):43-58.
49. Levy DL, Smith M, Robinson D, Jody D, Lerner G, Alvir J, Geisler SH, Szymanski SR, Gonzalez A, Mayerhoff DI et al: Methylphenidate increases thought disorder in recent onset schizophrenics, but not in normal controls. Biol Psychiatry (1993) 34(8):507-514.
50. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology (2004) 29(7):1363-1373.
51. Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswaraiah H, Gunduz-Bruce H, Schooler NR: Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry (2005) 66(7):839-843.
52. Poyurovsky M, Koren D, Gonopolsky I, Schneidman M, Fuchs C, Weizman A, Weizman R Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: An add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol (2003) 13(2):123-128.
53. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY: Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry (2001) 158(10):1722-1725.
54. Friedman JI, Ocampo R, Elbaz Z, Parrella M, White L, Bowler S, Davis KL, Harvey PD: The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol (2005) 25(3):237-242.
55. Hagan JJ, Jones DN: Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull (2005) 31(4):830-835.
56. Fiszdon JM, Bryson GJ, Wexler BE, Bell MD: Durability of cognitive remediation training in schizophrenia: Performance on two memory tasks at 6-month and 12-month follow-up. Psychiatry Res (2004) 125(1):1-7.
57. Hogarty GE, Flesher S, Ulrich R, Carter M, Greenwald D, Pogue-Gelle M, Kechavan M, Cooley S, DiBarry AL, Garrett A, Parepally H et al: Cognitive enhancement therapy for schizophrenia: Effects of a 2-year randomized trial on cognition and behavior. Arch Gen Psychiatry (2004) 61(9):866-876.
58. McGurk SR, Mueser KT, Pascaris A: Cognitive training and supported employment for persons with severe mental illness: One-year results from a randomized controlled trial. Schizophr Bull (2005) 31(4):898-909.
59. Wexler BE, Bell MD: Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr Bull (2005) 31(4):931-941.
60. Harvey PD, Bowie CR, Loebell A. Neuropsychological normalization with long-term atypical antipsychotic treatment: Results of a six-month randomized, double-blind comparison of ziprasidone vs olanzapine. J Neuropsychiatry Clin Neurosci (2006) 18(1):54-63
61. Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD: Determinants of real world functional performance in schizophrenia: Correlations with cognition, functional capacity, and symptoms. Am J Psychiatry (2006) 163(3):418-425.